VRTX FINANCIAL STATEMENTS

Vertex Pharmaceuticals Inc — balance sheet, income statement and cash flow trends

VRTXVertex Pharmaceuticals Inc

🇺🇸 USA · US · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue12.3 B $+10.4%

Gross Profit10.6 B $+10.7%

Operating Income4.8 B $—

EBITDA5.4 B $—

Net Income4.3 B $—

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
VRTX	10.4%	86.3%	44.0%	35.4%
CSL	4.8%	48.6%	32.8%	9.2%
TLX	56.3%	50.8%	3.0%	-0.9%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
VRTX	10.4%	86.3%	44.0%	35.4%
REGN	5.9%	84.5%	38.5%	29.6%
ALNY	82.6%	80.9%	21.6%	13.5%
RVMD	-100.0%	—	—	—
RPRX	7.8%	100.0%	69.6%	33.9%
MRNA	-29.1%	-13.9%	-129.7%	-143.6%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity19.4 B $73%
Current Liabilities3.9 B $15%
Long-term Liabilities3.2 B $12%

Key Figures

YoY change

Total Assets26.5 B $+15.8%

Total Liabilities7.1 B $+11.6%

Total Equity19.4 B $+17.4%

Cash & ST Investments7.2 B $+16.9%

Total Debt2 B $+20.5%

Net Debt-3.5 B $—

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
VRTX	3.02	10.3%	-0.98	73.1%
CSL	2.57	67.4%	2.22	49.2%
TLX	1.43	112.3%	13.13	35.1%
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
VRTX	3.02	10.3%	-0.98	73.1%
REGN	3.57	8.6%	-1.05	76.9%
ALNY	3.13	118.4%	-1.88	21.0%
RVMD	6.80	29.2%	1.12	66.6%
RPRX	2.66	130.0%	4.91	34.8%
MRNA	2.41	17.5%	1.35	64.5%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow4.2 B $—

Capital Expenditures530.3 M $+91.0%

Free Cash Flow3.7 B $—

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
VRTX	34.6%	30.3%	4.3%	97.7%
CSL	24.0%	20.3%	3.7%	261.5%
TLX	-2.2%	-6.3%	4.1%	243.1%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
VRTX	34.6%	30.3%	4.3%	97.7%
REGN	33.6%	27.9%	5.7%	113.3%
ALNY	16.6%	15.0%	1.7%	123.5%
RVMD	—	—	—	77.1%
RPRX	108.8%	108.8%	0.0%	320.7%
MRNA	-64.9%	-71.1%	6.2%	45.2%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on VRTX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.